Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine SR vs QD XR Bioavailability in Healthy Adults
NCT07465731Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration, Area Under the Concentration-time Curve From Time Zero to Infinity and 1 more. Started Oct 2022; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07465731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465731.